Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps on a Background of Nasal Corticosteroids (VIBRANT)

NCT06164704 is registered in ClinicalTrials.gov with Upstream Bio Inc. as lead sponsor.

NCT NCT06164704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06164704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps on a Background of Nasal Corticosteroids (VIBRANT)
Lead sponsor
Upstream Bio Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 18, 2023
Completion date
July 22, 2025
Enrollment
81 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

chronic rhinosinusitis with nasal polyps